Radiotherapy and erlotinib combined: Review of the preclinical and clinical evidence

Frontiers in Oncology

Volumn 2, Issue APR, 2012, Pages

  Mehta, Vivek K ^a  

^a SWEDISH MEDICAL CENTER   (United States)

Author keywords

Clinical; EGFR; Epidermal growth factor receptor; Erlotinib; Preclinical; Radiation; Radiotherapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEMCITABINE; PACLITAXEL; TEMOZOLOMIDE;

ACNE; APOPTOSIS; ASTHENIA; BRAIN METASTASIS; CELL CYCLE ARREST; CHEMORADIOTHERAPY; DERMATITIS; DIARRHEA; DNA DAMAGE; DNA REPAIR; DRUG DOSE REDUCTION; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS CANCER; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NAUSEA; NEOPLASM; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POPULATION DYNAMICS; PROGRESSION FREE SURVIVAL; RADIATION DERMATITIS; RADIATION DOSE; REVIEW; STEREOTACTIC RADIOSURGERY; TUMOR VOLUME; VOMITING; XEROSTOMIA;

EID: 84879031393     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2012.00031     Document Type: Review

References (52)

1. Arias de la Vega, F., Herruzo, I., de las Heras, M., de la Torre, A., del Rio, L., Contreras, J., Prieto, I., Garcia Saenz, J., and Calvo, F. A. (2008). Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous head and neck cancer (HNSCC): a GICOR phase I study. J. Clin. Oncol. 26, abstr. :6068.
2. Baumann, M., Krause, M., Dikomey, E., Dittmann, K., Dörr, W., Kasten-Pisula, U., and Rodemann, H. P. (2007). EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother. Oncol. 83, 238-248.
3. Berger, A. C., Garcia, M. Jr., Hoffman, J. P., Regine, W. F., Abrams, R. A., Safran, H., Konski, A., Benson, A. B. III, MacDonald, J., and Willett, C. G. (2008). Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J. Clin. Oncol. 26, 5918-5922.
4. Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., Ove, R., Kies, M. S., Baselga, J., Youssoufian, H., Amellal, N., Rowinsky, E. K., and Ang, K. K. (2006). Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578.
5. Bonner, J. A., Harari, P. M., Giralt, J., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Baselga, J., Spencer, S. A., Zhu, J., Youssoufian, H., Rowinsky, E. K., and Ang, K. K. (2010). Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11, 21-28.
6. Bozec, A., Sudaka, A., Fischel, J. L., Brunstein, M. C., Etienne-Grimaldi, M. C., and Milano, G. (2008). Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. Br. J. Cancer 99, 93-99.
7. Brown, P. D., Krishnan, S., Sarkaria, J., Wu, W., Mischel, P., Yong, W. H., Arusell, R., Jenkins, R. B., Buckner, J. C., and Giannini, C. (2008). A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM). J. Clin. Oncol. 26, abstr. :2016.
8. Cardenes, H. R., Chiorean, E. G., Perkins, S., DeWitt, J., Schmidt, M., Zyromski, N., and Howard, T. J. (2009). "Long-term follow-up of a pilot study using neoadjuvant gemcitabine, erlotinib and hypofractionated radiation therapy for potentially resectable pancreatic cancer," in Abstract 228 in 2009 Gastrointestinal Cancers Symposium Proceedings (San Francisco, CA: American Society of Clinical Oncology), January 15-17.
9. Chinnaiyan, P., Huang, S., Vallabhaneni, G., Armstrong, E., Varambally, S., Tomlins, S. A., Chinnaiyan, A. M., and Harari, P. M. (2005). Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 65, 3328-3335.
10. ClinicalTrials.gov. (2009a). Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC). Available at: http://www.clinicaltrial.gov/ct2/show/NCT00153803 [accessed September 28, 2011].
11. ClinicalTrials.gov. (2009b). Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients with Brain Metastases Secondary to Non-Small Cell Lung Cancer. Available at: http://www.clinicaltrial.gov/ct2/show/NCT00096265 [accessed September 28, 2011].
12. ClinicalTrials.gov. (2010). A Study of Tarceva (Erlotinib) in Patients with Resected Head and Neck Squamous Cell Cancer. Available at: http://www.clinicaltrial.gov/ct2/show/NCT00412217 [accessed September 28, 2011].
13. ClinicalTrials.gov. (2011). Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients with Stage III Non-Small Cell Lung Cancer that Cannot be Removed by Surgery. Available at: http://www.clinicaltrial.gov/ct2/show/NCT00553462 [accessed September 28, 2011].
14. de Groot, J. F., Gilbert, M. R., Aldape, K., Hess, K. R., Hanna, T. A., Ictech, S., Groves, M. D., Conrad, C., Colman, H., Puduvalli, V. K., Levin, V., and Yung, W. K. (2008). Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J. Neurooncol. 90, 89-97.
15. Dobelbower, M. C., Russo, S. M., Raisch, K. P., Seay, L. L., Clemons, L. K., Suter, S., Posey, J., and Bonner, J. A. (2006). Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. Anticancer Drugs 17, 95-102.
16. Dragovich, T., McCoy, S., Fenoglio-Preiser, C. M., Wang, J., Benedetti, J. K., Baker, A. F., Hackett, C. B., Urba, S. G., Zaner, K. S., Blanke, C. D., and Abbruzzese, J. L. (2006). Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J. Clin. Oncol. 24, 4922-4927.
17. Duffy, A., Kortmansky, J., Schwartz, G. K., Capanu, M., Puleio, S., Minsky, B., Saltz, L., Kelsen, D. P., and O'Reilly, E. M. (2008). A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann. Oncol. 19, 86-91.
18. Gerber, P. A., Enderlein, E., Homey, B., Muller, A., Boelke, E., and Budach, W. (2007). Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects. J. Clin. Oncol. 25, 4697-4698.
19. Hanawa, M., Suzuki, S., Dobashi, Y., Yamane, T., Kono, K., Enomoto, N., and Ooi, A. (2006). EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int. J. Cancer 118, 1173-1180.
20. Harari, P. M. (2004). Epidermal growth factor receptor inhibition strategies in oncology. Endocr. Relat. Cancer 11, 689-708.
21. Heimberger, A. B., Hlatky, R., Suki, D., Yang, D., Weinberg, J., Gilbert, M., Sawaya, R., and Aldape, K. (2005). Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin. Cancer Res. 11, 1462-1466.
22. Herchenhorn, D., Dias, F. L., Viegas, C. M. P., Federico, M. H., Araújo, C. M., Small, I., Bezerra, M., Fontão, K., Knust, R. E., Ferriera, C. G., and Martins, R. G. (2010). Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 78, 696-701.
23. Hsu, C. C., Herman, J. M., Corsini, M. M., Winter, J. M., Callister, M. D., Haddock, M. G., Cameron, J. L., Pawlik, T. M., Schulick, R. D., Wolfgang, C. L., Laheru, D. A., Farnell, M. B., Swartz, M. J., Gunderson, L. L., and Miller, R. C. (2010). Adjuvant chemoradiation for pancreatic adenocarcinoma: The Johns Hopkins Hospital-Mayo Clinic Collaborative Study. Ann. Surg. Oncol. 17, 981-990.
24. Iannitti, D., Dipetrillo, T., Akerman, P., Barnett, J. M., Maia-Acuna, C., Cruff, D., Miner, T., Martel, D., Cioffi, W., Remis, M., Kennedy, T., and Safran, H. (2005). Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am. J. Clin. Oncol. 28, 570-575.
25. Kim, E. S., Kies, M. S., Glisson, B. S., Tsao, A., Ginsberg, L. E., Holsinger, F. C., Burke, B. J., Truong, M., Papadimitrakopoulou, V. A., and Lippman, S. M. (2007). Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. J. Clin. Oncol. 25, abstr. :6013.
26. Kim, J. C., Ali, M. A., Nandi, A., Mukhopadhyay, P., Choy, H., Cao, C., and Saha, D. (2005a). Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib. Indian J. Biochem. Biophys. 42, 358-365.
27. Kim, K. S., Jeong, J. Y., Kim, Y. C., Na, K. J., Kim, Y. H., Ahn, S. J., Baek, S. M., Park, C. S., Park, C. M., Kim, Y. I., Lim, S. C., and Park, K. O. (2005b). Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin. Cancer Res. 11, 2244-2251.
28. Lacouture, M. E., Hwang, C., Marymont, M. H., and Patel, J. (2007). Temporal dependence of the effect of radiation on erlotinib-induced skin rash. J. Clin. Oncol. 25, 2140; discussion 2141.
29. Li, G., Hu, W., Wang, J., Deng, X., Zhang, P., Zhang, X., Xie, C., and Wu, S. (2010). Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 78, 1407-1412.
30. Lind, J. S., Lagerwaard, F. J., Smit, E. F., and Senan, S. (2009). Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 74, 1391-1396.
31. Marshall, J. L. (2011). Oncology-Colorectal Cancer: Medical Management. Available at: http://www.clinicaloptions.com/inPractice/Oncology/Gastrointestinal_Cancer/ch11_GI-CRC-Nonsurgical.aspx# [accessed February 22, 2012].
32. Martinez, E., Martinez, M., Viñolas, N., Casas, F., de la Torre, A., Valcarcel, F., Minguez, J., Paredes, A., Perez Casas, A., and Dómine, M. (2008). Feasibility and tolerability of the addition of erlotinib to 3D thoracic radiotherapy (RT) in patients (p) with unresectable NSCLC: a prospective randomized phase II study. J. Clin. Oncol. 26, abstr. :7563.
33. Meluch, A. A., Spigel, D., Burris, H. A., Lane, C., Peyton, J. D., Shipley, D., Rubin, M., Stipanov, M., Greco, F. A., and Hainsworth, J. D. (2009). Combined modality therapy with radiation therapy (RT), chemotherapy, bevacizumab, and erlotinib in the treatment of patients (pts) with locally advanced squamous carcinoma of the head and neck. J. Clin. Oncol. 27, abstr. :6012.
34. Mendelsohn, J. (2001). The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer 8, 3-9.
35. Mitra, S. S., and Simcock, R. (2006). Erlotinib induced skin rash spares skin in previous radiotherapy field. J. Clin. Oncol. 24, e28-e29.
36. Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., Campos, D., Lim, R., Ding, K., Clark, G., Voskoglou-Nomikos, T., Ptasynski, M., Parulekar, W., and National Cancer Institute of Canada Clinical Trials Group. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966.
37. National Comprehensive Cancer Network. (2011a). NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers, Version 2.2011. Available at: http://www.nccn.org/professionals/physician_gls/PDF/head-and-neck.pdf [accessed September 28, 2011].
38. National Comprehensive Cancer Network. (2011b). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Available at: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf [accessed September 28, 2011].
39. National Comprehensive Cancer Network. (2011c). NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Available at: http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf [accessed September 28, 2011].
40. Nyati, M. K., Morgan, M. A., Feng, F. Y., and Lawrence, T. S. (2006). Integration of EGFR inhibitors with radiochemotherapy. Nat. Rev. Cancer 6, 876-885.
41. Prados, M. D., Chang, S. M., Butowski, N., DeBoer, R., Parvataneni, R., Carliner, H., Kabuubi, P., Ayers-Ringler, J., Rabbitt, J., Page, M., Fedoroff, A., Sneed, P. K., Berger, M. S., McDermott, M. W., Parsa, A. T., Vandenberg, S., James, C. D., Lamborn, K. R., Stokoe, D., and Haas-Kogan, D. A. (2009). Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol. 27, 579-584.
42. Salomon, D. S., Brandt, R., Ciardiello, F., and Normanno, N. (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183-232.
43. Sarkaria, J. N., Carlson, B. L., Schroeder, M. A., Grogan, P., Brown, P. D., Giannini, C., Ballman, K. V., Kitange, G. J., Guha, A., Pandita, A., and James, C. D. (2006). Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin. Cancer Res. 12, 2264-2271.
44. Savvides, P., Agarwala, S. S., Greskovich, J., Argiris, A., Bokar, J., Cooney, M., Hoppel, C., Stepnick, D. W., Lavertu, P., and Remick, S. (2006). Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). J. Clin. Oncol. 24, abstr. :5545.
45. Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., van Kooten, M., Dediu, M., Findlay, B., Tu, D., Johnston, D., Bezjak, A., Clark, G., Santabárbara, P., Seymour, L., and National Cancer Institute of Canada Clinical Trials Group. (2005). Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132.
46. Silvano, G., Lazzari, G., Lovecchio, M., and Palazzo, C. (2008). Acute and fatal diarrhoea after erlotinib plus abdominal palliative hypofractionated radiotherapy in a metastatic non-small cell lung cancer patient: a case report. Lung Cancer 61, 270-273.
47. Soulieres, D., Senzer, N. N., Vokes, E. E., Hidalgo, M., Agarwala, S. S., and Siu, L. L. (2004). Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 22, 77-85.
48. Tortora, G., Gelardi, T., Ciardiello, F., and Bianco, R. (2007). The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy. Int. J. Biol. Markers 22(Suppl. 4), S47-S52.
49. von Pawel, J., Wagner, H., Duell, T., and Poellinger, B. (2008). Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reports. Onkologie 31, 123-126.
50. Wang, K. L., Wu, T. T., Choi, I. S., Wang, H., Resetkova, E., Correa, A. M., Hofstetter, W. L., Swisher, S. G., Ajani, J. A., Rashid, A., and Albarracin, C. T. (2007). Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 109, 658-667.
51. Yarden, Y. (2001). The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 37(Suppl. 4), S3-S8.
52. Zhu, C. Q., da Cunha Santos, G., Ding, K., Sakurada, A., Cutz, J. C., Liu, N., Zhang, T., Marrano, P., Whitehead, M., Squire, J. A., Kamel-Reid, S., Seymour, L., Shepherd, F. A., Tsao, M. S., and National Cancer Institute of Canada Clinical Trials Group Study BR.21. (2008). Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol. 26, 4268-4275.